LBI-HTA - Publications - Search - Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Breuer, J. and Joppi, R. and Poggiani, C. and Polkowska, M. and Nachtnebel, A. (2014): Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. DSD: Horizon Scanning in Oncology 44.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
428Kb
Abstract

In patients with advanced castration-resistant prostate cancer (CRPC), symptomatic bone metastases are frequently present. Xofigo® is a radiopharmaceutical that contains the active substance radium-223 dichloride, which targets bone tissue and bone metastases. The EMA licensed the agent for the treatment of adults with CRPC, symptomatic bone metastases and no known visceral metastases in November 2013, the FDA licensed Xofigo® for the same indication already in May 2013.
In a phase III trial, radium-223 was compared to placebo in 921 patients who either had progressed on docetaxel or were docetaxel-naive (i.e. they were either not eligible or chose not to receive it). The primary endpoint was overall survival (OS). Secondary endpoints included time to first symptomatic skeletal event, time to increase in total ALP/PSA levels or quality of life. For patients treated with radium-223, OS was extended by 3.6 months compared with the control group. Secondary endpoints improved in the intervention group compared with placebo, as well as quality of life. In terms of safety, the most frequent adverse events were bone pain, nausea, anaemia and diarrhoea in both groups.
With the licensing of radium-223, treatment options for patients with mCRPC are increased. The questions of how to best sequence or combine radium-223 with other already licensed agents such as docetaxel, cabazitaxel, abiraterone acetate, enzalutamide or mitoxantrone has not yet been a answered satisfactorily. Moreover, clarification is needed on optimised dosing for radium-223. Therefore, further clinical trials are needed.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:metastatic prostate cancer, radium-223, Xofigo®, oncology, castration-resistant
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 140-160 Urologic diseases
WJ Urogenital system > WJ 700-875 Male genitalia
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 44
Deposited on:07 Mar 2014 17:03
Last Modified:10 Mar 2014 17:23

Repository Staff Only: item control page